Concert Pharmaceuticals CNCE

$ 8.37 0.0%

Quarterly report 2022-Q3
added 11-07-2022

Concert Pharmaceuticals Balance Sheet 2011-2024 | CNCE

Annual Balance Sheet Concert Pharmaceuticals

	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
Net Debt	-127 M	-61.2 M	-36.8 M	-17.8 M	-27.7 M	-40.6 M	-92.5 M	-6.3 M	5.86 M	13.2 M	-14.6 M
Long Term Debt	13.9 M	-	-	-	-	-	-	-	7.35 M	15.5 M	8.05 M
Long Term Debt Current	1.16 M	931 K	268 K	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	17.9 M	18.7 M	16.1 M	8.86 M	9.23 M	9.67 M	11 M	136 M	132 M	126 M
Total Current Liabilities	16.1 M	10.2 M	17.3 M	8.75 M	6.44 M	5.57 M	6.63 M	18.6 M	-	-	-
Total Liabilities	53.1 M	28.1 M	36 M	24.8 M	15.3 M	14.8 M	16.3 M	29.6 M	152 M	140 M	136 M
Deferred Revenue	-	2.75 M	7.78 M	1.41 M	1.44 M	1.17 M	1.28 M	5.96 M	4.32 M	-	6.89 M
Retained Earnings	-349 M	-269 M	-195 M	-117 M	-76.2 M	-172 M	-121 M	-145 M	-114 M	-108 M	-87.1 M
Total Assets	165 M	159 M	137 M	193 M	212 M	100 M	147 M	84.5 M	39.8 M	33.1 M	49.4 M
Cash and Cash Equivalents	142 M	77.2 M	53 M	17.8 M	27.7 M	40.6 M	92.5 M	13.4 M	9.64 M	7.49 M	-
Book Value	112 M	131 M	101 M	168 M	196 M	85.6 M	131 M	54.8 M	-112 M	-107 M	-86.7 M
Total Shareholders Equity	112 M	131 M	101 M	168 M	196 M	85.6 M	131 M	54.8 M	-112 M	-107 M	-

All numbers in USD currency

Quarterly Balance Sheet Concert Pharmaceuticals

	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
Long Term Debt	-	12.9 M	-	13.6 M	13.9 M	14.2 M	14.5 M	14.8 M	15.1 M	15.1 M	15.1 M	15.1 M	16 M	16 M	16 M	16 M	-	-	-	-	-	-	29.2 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Non Current Liabilities	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Total Liabilities	-	37.9 M	-	52.8 M	53.1 M	29 M	26 M	26 M	28.1 M	28.1 M	28.1 M	28.1 M	36 M	36 M	36 M	36 M	24.8 M	24.8 M	24.8 M	24.8 M	15.3 M	15.3 M	15.3 M	15.3 M	14.8 M	14.8 M	14.8 M	14.8 M	16.3 M	16.3 M	16.3 M	16.3 M	29.6 M	29.6 M	29.6 M	29.6 M	39.6 M	39.6 M	39.6 M	39.6 M	-	-	-	-	-	-	-	-
Deferred Revenue	-	-	-	-	-	-	-	-	-	-	1.41 M	7.78 M	7.78 M	7.78 M	7.78 M	7.78 M	1.41 M	1.41 M	1.41 M	1.41 M	1.44 M	1.39 M	1.17 M	1.16 M	1.17 M	1.17 M	1.17 M	1.17 M	1.28 M	1.28 M	1.28 M	1.28 M	5.96 M	5.96 M	5.96 M	5.96 M	4.32 M	4.32 M	4.32 M	4.32 M	-	-	-	-	-	-	-	-
Retained Earnings	-	-440 M	-	-387 M	-349 M	-313 M	-287 M	-292 M	-269 M	-269 M	-269 M	-269 M	-195 M	-195 M	-195 M	-195 M	-117 M	-117 M	-117 M	-117 M	-76.2 M	-76.2 M	-76.2 M	-76.2 M	-172 M	-172 M	-172 M	-172 M	-121 M	-121 M	-121 M	-121 M	-145 M	-145 M	-145 M	-145 M	-114 M	-114 M	-114 M	-114 M	-	-	-	-	-	-	-	-
Total Assets	-	171 M	-	129 M	165 M	128 M	149 M	140 M	159 M	159 M	159 M	159 M	137 M	137 M	137 M	137 M	193 M	193 M	193 M	193 M	212 M	212 M	212 M	212 M	100 M	100 M	100 M	100 M	147 M	147 M	147 M	147 M	84.5 M	84.5 M	84.5 M	84.5 M	39.8 M	39.8 M	39.8 M	39.8 M	-	-	-	-	-	-	-	-
Cash and Cash Equivalents	-	95.2 M	-	59.4 M	142 M	104 M	122 M	89.8 M	77.2 M	77.2 M	77.2 M	77.2 M	53 M	53 M	53 M	53 M	17.8 M	17.8 M	17.8 M	17.8 M	27.7 M	27.7 M	27.7 M	27.7 M	40.6 M	40.6 M	40.6 M	40.6 M	92.5 M	92.5 M	92.5 M	92.5 M	13.4 M	13.4 M	13.4 M	13.4 M	9.64 M	9.64 M	9.64 M	9.64 M	7.49 M	-	-	-	22.9 M	-	-	-
Book Value	-	133 M	-	76.6 M	112 M	99.2 M	123 M	114 M	131 M	131 M	131 M	131 M	101 M	101 M	101 M	101 M	168 M	168 M	168 M	168 M	196 M	196 M	196 M	196 M	85.6 M	85.6 M	85.6 M	85.6 M	131 M	131 M	131 M	131 M	54.8 M	54.8 M	54.8 M	54.8 M	140 K	140 K	140 K	140 K	-	-	-	-	-	-	-	-
Total Shareholders Equity	-	133 M	128 M	76.6 M	112 M	99.2 M	123 M	114 M	131 M	131 M	131 M	131 M	101 M	101 M	101 M	101 M	168 M	168 M	168 M	168 M	196 M	196 M	196 M	196 M	85.6 M	85.6 M	85.6 M	85.6 M	131 M	131 M	131 M	131 M	54.8 M	54.8 M	54.8 M	54.8 M	-112 M	-112 M	-112 M	-112 M	-107 M	-	-	-	-86.7 M	-	-	-

All numbers in USD currency